After initial clinical data are compiled, the investors may choose to put in an additional
"There are some people who have immune systems that stop working to fight a cancer, and then the cancer grows," Chief Executive
Immune Design is developing immune-based therapies to fight cancer and other chronic diseases. The new funds will primarily be used to advance the company's cancer-immunotherapy product pipeline, including starting clinical trials for its lead therapeutic candidates that target solid tumor cancers. The company has yet to disclose anything more about the specific cancer types.
This financing round was led by
While the clinical trial will take place in
Over the past two months, Immune Design has expanded its management team, adding four veteran executives who will work out of a new
Depending on the results of the first two stages of clinical trials over the next three years, the third stage, which is aimed at getting
This is the first time the company's cancer immunotherapies are going to clinical trial, Paya said. "We are all very excited to test these new technologies that nobody has tested before in cancer patients," he said.
(c)2013 The Seattle Times
Visit The Seattle Times at www.seattletimes.com
Distributed by MCT Information Services